Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Frank Stephen Hodi, M.D.


Novel HSP90 and EGFR inhibitors as potential therapeutics for melanoma
Full Time/Year Long, 08/29/11 - 05/04/12

The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. U54CA244726 (MOONEY, DAVID J) Sep 25, 2019 - Aug 31, 2024
    Biomaterials to Create T Cell Immunity
    Role: Co-Principal Investigator
  2. U24CA224331 (WU, CATHERINE JU-YING) Sep 30, 2017 - Jun 30, 2022
    Cancer Immune Monitoring and Analysis Center
    Role: Co-Principal Investigator
  3. U01CA214369 (MOONEY, DAVID J) Apr 1, 2017 - Mar 31, 2022
    3D Models of Immunotherapy
    Role: Co-Principal Investigator
  4. R01CA158467 (FRANK, MARKUS H.) Sep 1, 2012 - Jun 30, 2017
    Immunology of human malignant melanoma initiating cells
    Role: Co-Principal Investigator
  5. R21CA143832 (HODI, FRANK S) Jul 1, 2010 - Jun 30, 2012
    Bevacizumab plus Ipilimumab in Unresectable Stage III or Stage IV Melanoma
    Role: Principal Investigator

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Flaherty KT, Hodi FS, Fisher DE. Author Correction: From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer. 2020 Oct 12. PMID: 33046838.
    Citations:    Fields:    
  2. Qian JM, Martin AM, Martin K, Hammoudeh L, Catalano PJ, Hodi FS, Cagney DN, Haas-Kogan DA, Schoenfeld JD, Aizer AA. Response rate and local recurrence after concurrent immune checkpoint therapy and radiotherapy for non-small cell lung cancer and melanoma brain metastases. Cancer. 2020 Sep 14. PMID: 32926760.
    Citations:    Fields:    
  3. Miller PG, Sperling AS, Gibson CJ, Pozdnyakova O, Wong WJ, Manos MP, Buchbinder EI, Hodi FS, Ebert BL, Davids MS. A deep molecular response of splenic marginal zone lymphoma to front-line checkpoint blockade. Haematologica. 2020 Sep 14; Online ahead of print. PMID: 33054119.